Inhibitors of human immunodeficiency virus replication

A compound of Formula I, including pharmaceutically acceptable salts thereof:

• wherein:
• R is selected from the group of alkyl, alkenyl, alkoxy, alkylthioxy, C5-C8 bicycloalkyl, C3-C7 cycloalkyl, aryl, and 5-6 member heteroaryl;
• and is substituted with 0-3 substituents selected from the group of alkyl, alkenyloxy, alkoxycarbonyl, alkylcarbonylamino, aminocarbonyl, aryl, benzyloxy, cyano, cycloalkoxy, cycloalkyl, halo, haloalkyl, haloalkoxy, hydroxy and (morpholinyl)sulfonyl
• R1 is selected from the group of alkyl, cycloalkyl, (cycloalkyl)alkyl, aryl, and 5-6 member heteroaryl;
• and is substituted with 0-3 substituents selected from the group of alkyl, alkoxy, alkoxycarbonyl, aryl, cyano, cycloalkyl, halo, haloalkoxy, haloalkyl, 5-6 member heteroaryl, nitro, and N—R2R3, where R2 and R3 are each independently selected from H, alkyl, and cycloalkyl, or R2 and R3 together form heterocycles comprised of 1-3 rings;
• A is a five or six-member heteroaryl ring optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkyl, halo and haloalkyl;
• and
• B is selected from the group of alkyl, aryl, arylalkyl, C3-C9 cycloalkyl, and 5-6 member heteroaryl, and is substituted with 0-3 substituents selected from the group of alkyl, alkylsulphonyl, alkoxy, alkylaryl, allyloxy, arylalkoxy, cycloalkoxy, cycloalkyl, halo, haloalkoxy, heteroarylcycloalkyl amido, hydroxymethyl, nitro, —CN, —COOR2, —NR2R3, —N(R2)COOR3, —CONR2R3, NH—CO-alkyl, and morpholinyl.